FibroBiologics, Inc. Common Stock (FBLG) Stock

FibroBiologics, Inc. Common Stock (FBLG) is a Healthcare stock trading at $0.63 (as of 2026-07-27), with a market capitalization of $4.17M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

FibroBiologics, Inc. develops and commercializes fibroblast-based therapies in the United States. Its development pipeline includes CybroCell for degenerative disc disease, CYMS101 for multiple sclerosis, and CYWC628 for wound healing, with earlier-stage research on CYTER915, CYPS317, and TCB190.

Understand FibroBiologics, Inc. Common Stock: how it makes money

FibroBiologics develops and commercializes fibroblast-based cell therapies in the United States, aiming to make money by selling its therapies after they complete development and achieve commercialization.

Because FibroBiologics is a clinical-stage cell therapy developer, its long-term profit potential depends primarily on advancing multiple therapy programs (for example CybroCell, CYMS101, and CYWC628) to successful clinical outcomes and eventual commercialization.

Business quality (Weak): Pipeline breadth is clear, but the provided data shows no segment breakdown and no operating KPIs, and the latest period reflects zero revenue with a very negative operating margin.

Bull case

  • Multiple clinical-stage therapy programs: The company is developing CybroCell (degenerative disc disease), CYMS101 (multiple sclerosis), and CYWC628 (wound healing), plus earlier-stage research programs such as CYTER915, CYPS317, and TCB190.
  • Built around a consistent platform approach: All named programs are described as fibroblast-based therapies, which can support shared development learning across indications.

Bear case

  • Clinical development risk before commercial scale: As a clinical-stage company, progress and outcomes for its therapies are uncertain, and delays or failures can affect the path to commercialization.
  • Latest period shows no revenue and significant operating losses: In the period ended 2026-03-31, revenue is shown as 0.0B and the operating margin is deeply negative (-25340.0%).
Valuation — source: SEC EDGAR (first-party)
Price$0.63
Market Cap$4.17M
Price / Book0.90
Price / Sales32.61
FCF Yield-715.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$247000.00
Net Margin-7549.0%
Revenue Growth (YoY)-1.6%
EPS Growth (YoY)23.5%
FCF Growth (YoY)37.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.65 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($273677.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPeter O'Heeron
Employees13
CountryUS
IPO Date2024-02-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Lakewood-Amedex Biotherapeutics Inc. (LABT)
  • Aptevo Therapeutics Inc. (APVO)
  • Revelation Biosciences, Inc. (REVB)
  • GRI Bio, Inc. (GRI)
  • Genprex, Inc. (GNPX)
  • Artelo Biosciences, Inc. (ARTL)
  • 60 Degrees Pharmaceuticals, Inc. (SXTP)
  • Onconetix, Inc. (ONCO)
FBLG earnings history · FBLG institutional & insider holders · FBLG KPIs & operating metrics · FBLG financials · FBLG investor presentations & press releases · FBLG SEC filings · FBLG peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-27.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.